Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Free Cash Flow (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Free Cash Flow readings, the most recent being -$6.6 million for Q4 2024.

  • On a quarterly basis, Free Cash Flow fell 48.01% to -$6.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$28.6 million, a 56.69% decrease, with the full-year FY2025 number at -$31.3 million, down 9.4% from a year prior.
  • Free Cash Flow hit -$6.6 million in Q4 2024 for Unicycive Therapeutics, up from -$9.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.0 million in Q1 2022 to a low of -$9.3 million in Q3 2024.
  • Median Free Cash Flow over the past 3 years was -$5.0 million (2023), compared with a mean of -$5.2 million.
  • Biggest five-year swings in Free Cash Flow: rose 27.04% in 2023 and later crashed 109.77% in 2024.
  • Unicycive Therapeutics' Free Cash Flow stood at -$6.1 million in 2022, then rose by 27.04% to -$4.4 million in 2023, then tumbled by 48.01% to -$6.6 million in 2024.
  • The last three reported values for Free Cash Flow were -$6.6 million (Q4 2024), -$9.3 million (Q3 2024), and -$6.3 million (Q2 2024) per Business Quant data.